Home > Boards > US OTC > Biotechs > NorthWest Biotherapeutics Inc. (NWBO)

survivor1x,Matured DCs are required for mobility to the

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Doc logic Member Profile
 
Followed By 46
Posts 5,053
Boards Moderated 0
Alias Born 01/26/16
160x600 placeholder
CLS Holdings (CLSH) Record Sales Just Reported - Most Undervalued Cannabis Stocks InvestorsHub NewsWire - 9/10/2019 7:00:09 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/9/2019 4:22:51 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/22/2019 5:05:19 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 7/18/2019 6:02:10 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 7/17/2019 5:24:27 PM
Biotech Companies with Recent and Potential Near-Term Catalysts InvestorsHub NewsWire - 7/15/2019 8:15:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/28/2019 12:11:21 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/10/2019 5:24:36 PM
Annual Report (10-k) Edgar (US Regulatory) - 4/2/2019 5:23:33 PM
Notification That Annual Report Will Be Submitted Late (nt 10-k) Edgar (US Regulatory) - 3/19/2019 5:19:39 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2019 3:33:33 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2019 3:20:35 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/7/2019 5:26:54 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 1/8/2019 6:04:56 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/20/2018 4:18:14 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/11/2018 4:17:32 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/28/2018 5:28:53 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/23/2018 1:44:13 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/16/2018 5:38:07 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 11/15/2018 3:15:58 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/13/2018 4:49:26 PM
Doc logic   Wednesday, 09/11/19 11:19:51 PM
Re: survivor1x post# 243778
Post # of 244450 
survivor1x,

Matured DCs are required for mobility to the lymph zone in the skin of the upper arms which in L's case is away from the tumor draining lymph nodes in or near the brain that are heavily influenced by the compromised signaling caused by the cancer itself. The actual maturation/activation process for L starts off similarly ex vivo so yes, the teenagers pick up the antigens in the lysate like Direct would do en vivo but then are matured so that the information gathered can be mobilized to move into the lymph zone instead of remaining at the site of injection and dying or all being killed off by a process called phagocytosis. There are other things that were learned from Direct Phase 1, though, that may have played a part in any "optimization". Not to worry, NWBO has some smart cookies that have figured out how to use the valuable information these trials have generated. Best wishes.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist